Search
Repligen Corp
RGENAdd to Watchlist
173.490USD
+5.010+2.97%
Close 11-06 16:00（ET）
11.09BMarket Cap
190.08P/E TTM
Repligen Corp (RGEN) Stock Price Target & Forecast
Analyst Rating
Based on 21 analysts giving stock ratings to Repligen Corp in the past month.
Buy
5 Strong Buy
12 Buy
4 Hold
0 Sell
0 Strong Sell
Target Price
205.626USD+16.21%
RGEN Analyst Recommendation Trends
In the current month, RGEN has received 12 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. RGEN average Analyst price target in the last month is 205.626.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
5
5
5
5
5
5
12
13
14
13
13
14
13
13
4
3
3
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21
21
22
22
22
23
22
22
RGEN Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Stryker Corp
SYK
10
14
6
0
0
30
Dexcom Inc
DXCM
13
12
4
0
0
29
Medtronic PLC
MDT
8
11
10
0
0
29
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Guardant Health Inc
GH
12
14
2
0
0
28
Abbott Laboratories
ABT
11
13
4
0
0
28
Zimmer Biomet Holdings Inc
ZBH
2
5
20
0
0
27
Insulet Corp
PODD
7
7
12
0
0
26
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Alcon AG
ALC
6
9
3
1
0
19
Financial Forecasting
Based on analysts' estimates, RGEN EPS is projected to reach 0.524 in FY2026Q4, following reported EPS of -0.680 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
0.39
0.45
0.46
0.52
0.60
Actual
0.15
0.09
-0.68
--
--
Surprise
-61.70%
-80.21%
-247.49%
--
--
FAQs
What is Repligen Corp's expected revenue for the next quarter?
Repligen Corp's expected revenue is 239.88M.
What is Repligen Corp's price target?
Analysts forecast that Repligen Corp's price target is USD 205.63, with the highest forecast at USD 235.00 and the lowest forecast at USD 175.00.
How have Repligen CorpRGEN's recent earnings per share performed?
The market expectation was USD -0.68, while Repligen CorpRGEN's earnings per share (EPS) for the previous quarter was USD 0.09. EPS for the next quarter is expected at USD 0.52.
What is the analyst rating for Repligen Corp?
Based on the ratings of Repligen Corp's stock from 21 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.